ࡱ> Root EntryRoot Entryb5"FileHeaderdDocInfoLHwpSummaryInformation.Bu BodyText b5b5PrvImage uPrvTextDocOptions b5b5Scripts b5b5JScriptVersion k DefaultJScripth_LinkDocl  !"#$%&'()*+,-./0123456789:;<=>?@ACDEFGHIJKMNOPQRSTUVWXYZ[\]^_`abcefgijmnopqrstvwxyz{|}~<(|x 8 ]> The new network of sphinogolipid metabolism in the development of non-alcholic steatohepatitis Nonalcoholic fatty liver disease (NAFLD) has become a major health issue worldwide. Approximately 10 20% of patients with NAFLD develop non-alcoholic steatohepatitis (NASH), an advanced stage of NAFLD that may subsequently progress to liver cirrhosis and hepatocellular carcinoma. The mechanism by which simple steatosis progresses to NASH and liver fibrosis is not completely understood, and an effective treatment for halting the progression of NASH is yet to be discovered. Lipotoxic hepatocyte death may be the primary lesion that causes liver inflammation and fibrosis. Damage-associated molecular patterns released from dying hepatocytes may activate hepatic macrophages, and secretion of proinflammatory and fibrogenic cytokines from macrophages promotes hepatic stellate cells activation. But the mechanisms of lipotoxicity are not fully defined. Sphingolipids mediate liver injury, but their linkGIF89aɻxxxkkk]]]PPPCCC555((( d`LH00`Hذ̘`H0|pdXL@`0H `H0`dHL`H0xp`XH@0d LȰ``HH00dLؘȀ`H0xp`XH@d0L `H0d`LH`H0|pdXL@0`$H`dHL00`HذȘdL0xp`XH@0` HdH0ȳ``HHdL0xp`XH@`0H Ը̰ĠऀؘpȈXxHp@h@d8`8X0xT0pH dxddxd`d`p`|``x`p``x`!, H*\ȰÇ#JHŋ3jȱǏ CIɓ(S\ɲ˗0cʜI͛8sɳϟ@ JѣH*]ʴӧPJJիXjʵׯ`ÊK٩Ҫ]˶۷pʝKݸg˷_`ÃL1ACblj'g&ž)Gm3ҏOl1iҢ+fZ`ӖoL;BݜsOnk}pУKNسkߎOy%6Oy6beJ|'d phW؂D݆\m Z! ڇba̡0.a2֨<@)9or_˥FܑfdL32 (#cVmb Τ!^xqi&#ږdb>I䟀؞z.gf~&[=ꡚYie$fMιi(L`f:cZyZh痟*k檫xz(EX:`gmF[it*ft$-Zvr;%bډ+]kkB#j,Gߓ Vz4z+%N[/-wΪ鷋^&pK*˧y쾗Z;n,yɗsC67윒 ҴRX+3[ZҚr*S]Z2Z'!Ld_hd&,ho[SV_yqɞg8e" ]Ymh[o͹q]lnbuӳqII~Y>m)עWKzo-tamHHF ("k̢$@1bьd%*itI&ґ|d%Ҕo,eHZr%4dWB:ؐ\$yGd҉D*))Bh&Ӎ$&3Nӛd-IrL:v~ @JЂMBІ:D'JъZͨF7юz HGJҒ(MJWҖ0LgJӚ& ;`a``a`0Ex 0p|    (08FThe new network of sphinogolipid metabolism in the development of nonGACHON2022D 3 11|Section0u{ | $ 1:41:52GACHON-9, 1, 1, 5216 WIN32LEWindows_Unknown_Version@P;S5@b5@WkA;3MSb[=?@'Y?@Zܪ4j)Eœ^cΡe lY1,o;/eC hRۡ0p[:|xdݱ9` 2, /CvE8 '0f1=mGa.0IYĐH}( aN?-9YQo/0h׮rL8]3؂.竑 [N'EH~&M?ECZݻ,ϣK.cׅθL\tMzYyveͯAZF˸97 ~I~a{]^/W6ױ;u_a Lpsfִ[w).VM4r$H47"bMhjꍡ1(Dl}&鴗/JVqA21l-tJjKlLcX5^M`[mIfsΝdclrG+]e}?BPhMocglquKҵ+&yy.\Ey_!6ODYy06y FxV 7) a7o~!d@IZ rAI.m$\ 5%yP̿'J A&B(0~aMPn5t\N,β#Z:v媁fDqp 9<UPmx[x$6 ((K@HPxx;%NnAz?werb;>!0~+&(W\.U=(;N mv7E(Gq~ W{%n6 ' xc׻7>Cbe(s!Gуh0j3zy8|^C1%y&ΨTPQ)ZNTzR]={Q$ju8_oMMtXP%쎹IGs'Sd.}D5K=S);JII3ޓrIh^%pϼxq~c~57wrt/T+O}d̍:bRѬk%]ŵ?u{Iy*2Tn)^MiMozCoWoʗHWP Document Fileu@DO 6C,H,#GB!k0~ 6*7=M*Z:ҙ#?*?ӿT@Y~X+mj3'm[v|:j)%C$Mϼ5#cd߈activate hepatic macrophages, and secretion of proinflammatory and fibrogenic cytokines from macrophages promotes hepatic stellate cells activation. But the mechanisms of lipotoxicity are not fully defined. Sphingolipids mediate liver injury, but their link VME~='Dl 1n?lv7Ljn{!V$h@o !xQAUqGAI|?U=^z}UM ,[8`5i)1Fz{U3vܞ,鵱yKQtl'Dety9 < ܞiʏ?gbiܲa:B/*wuY2Lgq9"lÒYNw. N[j$3/W֬mkݵUJs:JhmZrgg U8Dq7tu߭rO *=ƴ&1%Ҙ~@5#*S,*2+07n-rd~޻jnWHP;Gh;دB` ChbCZ]l \k.|3:8/ؿ-@.5v/DP>dM]Ÿa1Y㬊X/K攳2f';8?ǔG>;3 f0h=Lj1% 1>gaA.cTUf)#"GaTiWcXfI@p}80]aglŕ{1y'ǬvK3$ωpK$0>wo4"ZӢ#SxY~$/2Fx.,`3ۖI,%k* ](C3%{*Ț a;?x!ab?3],sNSSlO9f^`4t3+\u^7e~^,SE .˼2hP~L }b(sJm9繾ϝj܉?_wlt/^/e.